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Summary
Background: IgG4 antibodies have been suggested to play a protective role in the
translation of peanut sensitization into peanut allergy. Whether they have added
value as diagnostic read‐out has not yet been reported.
Objective: To evaluate whether (a) peanut‐specific IgG, IgG4 and/or IgA antibodies
are associated with tolerance and/or less severe reactions and (b) they can improve
IgE‐based diagnostic tests.
Methods: Sera of 137 patients with challenge‐proven peanut allergy and of 25 sub-
jects that tolerated peanut, both with known IgE profiles to peanut extract and five
individual peanut allergens, were analyzed for specific IgG and IgG4. Antibody levels
and ratios thereof were associated with challenge outcome including symptom
severity grades. For comparison of the discriminative performance, receiver operat-
ing characteristic curve (ROC) analysis was used.
Results: IgE against Ara h 2 was significantly higher in allergic than in tolerant patients
and associated with severity of reactions (P < 0.001) with substantial diagnostic capa-
bility (AUC 0.91, 95%CI 0.87‐0.96 and 0.80, 95%CI 0.73‐0.87, respectively). IgG and
IgG4 were also positively associated albeit significantly weaker (AUCs from 0.65 to
0.72). On the other hand, ratios of IgG and IgG4 over IgE were greater in patients that
were tolerant or had mild symptoms as compared to severe patients but they did not
predict challenge outcomes better than IgE alone (AUCs from 0.54 to 0.89).
Conclusion: IgE against Ara h 2 is the best biomarker for predicting peanut chal-
lenge outcomes including severity and IgG and IgG4 antibody ratios over IgE do not
improve these outcomes.
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1 | INTRODUCTION
Allergic symptoms to peanut are mediated by IgE antibodies against
specific components of peanut, of which Ara h 1, 2, 3 and 6 are gen-
erally considered to be the major allergens. Other components are
Ara h 8 (Bet v 1 homologue) and Ara h 9 (lipid transfer protein), but
sensitization to these molecules is well established to be indirect
(cross‐reactivity). However, specific IgE against peanut allergens is
also found in serum of subjects that tolerate peanuts. Although in tol-
erant but sensitized subjects IgE levels are usually lower than in pea-
nut allergic patients, they show large overlap between both groups.
Why similar IgE levels sometimes translate into tolerance and some-
times into clinical allergy is still not fully understood. In addition, it is
also not clear why symptom severity varies between patients.1
Altogether, this limits the prognostic value of serum IgE tests
and their contribution to the diagnosis of peanut allergy. Tradition-
ally, serum IgE tests like ImmunoCAP measure IgE against whole
peanut extract. With the advent of component‐resolved diagnosis
(CRD), the potential of serum IgE testing to distinguish between tol-
erance and allergy, and beyond that, to better assess the risk of sev-
ere reactions, has significantly increased. In multiple studies, IgE to
Ara h 2 has been reported to perform better than extract in discrimi-
nating peanut allergic patients from tolerant sensitized subjects, both
in children2-8 and adults.9 More recently, IgE against Ara h 6 has
been reported to perform similarly well as Ara h 2 as biomarker for
peanut allergy.10-13 This is not surprising knowing that both allergens
are closely related 2S albumins sharing (cross‐reactive) IgE epi-
topes.14 An association of IgE against Ara h 2 with symptom severity
has also been reported, both in children and adults6,9,15,16 as well as
it being a good discriminator between mild and severe symp-
toms,12,17 but there are also conflicting reports.2,7,18,19
Not only IgE against peanut extract but also against Ara h 2 can
be found in peanut‐tolerant subjects. What tips the balance towards
tolerance or (severe life‐threatening) allergy? One hypothesis is that
other antibody isotypes, such as IgG (or more specifically IgG4) and
possibly IgA play a protective role by functionally acting as blocking
antibodies. Several mechanisms have been proposed for the protec-
tive role of blocking antibodies, the most important being the block-
ing of IgE‐facilitated antigen presentation to T cells by CD23‐
carrying antigen presenting cells (B‐cells) and the blocking of aller-
gen-induced mast cell/basophil triggering through mixed IgE/IgG4‐
receptor cross‐linking.20 Whether identical epitopes for IgE, IgG, and
IgG4 are a prerequisite for blocking activity is still not fully under-
stood.21,22 Patients that outgrow a food allergy or successfully
undergo immunotherapy have been shown to have increased specific
IgG4 levels.
23,24 Early introduction of peanut in children at high risk
of developing food allergy showed that a lower ratio of IgG4/IgE
against peanut was associated with peanut allergy, suggesting a pro-
tective role for blocking antibodies.25 Santos et al26 also reported
that the ratio of IgG4/IgE was significantly higher in sensitized but
tolerant subjects than in those sensitized with allergic symptoms.
Song et al15 found a similar association with the outcome of a food
challenge, but ratios did not correlate with symptom severity.
Altogether, these reports suggest that antibody isotypes like IgG,
IgG4 and possibly IgA functionally act as blocking antibodies, counter-
acting the symptom‐inducing role of IgE antibodies. However, it has
not been evaluated whether measurement of these antibodies may
complement serum IgE testing to improve allergy diagnosis, on top of
the improvements already achieved by the introduction of CRD.
The aim of this study was therefore to (a) explore associations
between peanut extract‐ and component‐specific IgE, IgG, IgG4 and
IgA antibodies and the outcome of peanut challenges including
symptom severity grades; (b) evaluate the diagnostic accuracy of
observed antibody levels and ratios thereof to discriminate between
tolerant but sensitized and allergic patients as well as between
patients with a mild peanut allergy and a more severe phenotype. To
this end, sera of peanut sensitized tolerant and allergic subjects
(n = 162) were analyzed by ImmunoCAP for different isotype anti-
body reactivities against peanut extract, Ara h 1, Ara h 2, Ara h 3,
Ara h 8 and Ara h 9.
2 | METHODS
2.1 | Patient selection, peanut challenges and
classification of severity (reference standard)
Data and serum from children and adults with a history of peanut
allergy visiting the Allergy Center at Odense University Hospital, Den-
mark were consecutively collected between March 2003 and March
2009 and stored for later analyses. All subjects (or their legal represen-
tatives) signed an informed consent form. The project was approved
by the Danish Data Inspectorate Board, licence no. 2012‐58‐0018.
We included 162 sensitized subjects that had undergone a food
challenge to confirm or exclude peanut allergy, as previously
described,5 and of whom a blood sample was available that had been
taken and stored within a year from the challenge. Twenty‐five of
the 162 patients were negative during their first challenges and of
the remaining 137 positives, 42 were followed longitudinally with
one or multiple re‐challenges and matched blood samples. Six of
these 42 patients later developed tolerance to peanut verified by a
negative challenge. All children younger than 4 years of age and
patients with compliance problems underwent OFCs (n = 122). All
other patients had a DBPCFC (n = 40). In total, 212 challenges were
performed of which 181(85.4%) were positive.
Details of the challenges and threshold doses were published
elsewhere.27 Patients were challenged with whole roasted unsalted
peanuts under guidance of trained staff following the European
Academy of Allergy and Clinical Immunology (EAACI) guidelines.28
Allergic reactions during the challenge were graded according to
Sampson et al29 as follows: oral symptoms only (I), angioedema, gen-
eralized urticaria and/or emesis (II), rhinorrhea and/or repetitive vom-
iting (III), diarrhoea and asthma (IV). None of the patients showed
any loss of bowel control, respiratory arrest or severe bradycardia
and/or hypotension (V). Primary outcomes of this study were being
tolerant or have a mild positive reaction to the challenge (grade I‐II)
and having (more) severe symptoms (grade III and IV).
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2.2 | Sensitization measurements (index tests)
Blood samples were stored at −25°C for later analysis; specific and
total IgE was measured by ImmunoCAP at Odense University
Hospital, whereas specific IgG, IgG4 and IgA were tested by
ImmunoCAP at the Academic Medical Centre, Amsterdam, the
Netherlands, according to the manufacturer's instructions (Thermo
Fisher Scientific, Uppsala, Sweden). Serum was tested for specific
IgE, IgG, IgG4 and IgA antibodies against whole peanut (extract) and
peanut components rAra h 1 (7S globulin), rAra h 2 (2S albumin),
rAra h 3(11S globulin), rAra h 8(Bet v1 homologue) and rAra h 9
(lipid transfer protein).
2.3 | Statistical analysis
Differences in patient characteristics and antibody serum levels were
compared between tolerant and allergic subjects and between the
severity of the allergic reactions (tolerant, grade I, II, III or IV). We
used generalized linear mixed‐effect models to adjust for patients
with measurements on multiple time‐points. Ratios were calculated
for IgG/IgE, IgG4/IgE and IgA/IgE. All values were converted from kilo
units per litre IgE (kUA/L), micrograms per litre IgG4 (μg/L) and mil-
ligram per litre IgG and IgA (mg/L) to nanogram per millilitre (ng/mL).
Because correlation analyses were comparable when using random
effect models to adjust for multiple testing, Spearman's rank correla-
tion coefficients (rho) are reported for correlations between IgE, IgG,
IgG4 and IgA antibodies and the challenge cumulative dose. P‐values
were adjusted using Bonferroni correction for multiple testing.
For comparison of the discriminative performance of all antibody
isotypes and the ratio's receiver operating characteristic curve (ROC)
analysis was used. We calculated the area under the ROC curve
(AUC) for discriminating between tolerant and allergic patients and
for discriminating between patients with mild‐to‐moderate (tolerant,
grade I‐II) and patients with severe (grade III and IV) symptoms. We
compared AUCs of the different antibodies isotypes/subclasses using
DeLong tests. Of the patients with multiple challenges, only the ini-
tial challenge was included in the ROC analysis.
Finally, we selected the markers that performed best according
to the ROC analysis. Optimal cut‐off values corresponding to the
best sensitivity and specificity are data‐driven and consequently
prone to bias.30 Therefore, cut‐off values were drawn from both a
sensitivity and a specificity of 95%, respectively, or if not attainable
closest to 95%. From these cut‐offs, the corresponding specificity or
sensitivity, and positive predictive values (PPV) and negative predic-
tive values (NPV) were calculated. We used R software version 3.2.4
for all statistical analyses.
3 | RESULTS
3.1 | Patient characteristics
The age of the 162 patients ranged from 0.6‐26.6 years, with a
mean age of 6.5 (SD 4.4). The majority was younger than 18 years
of age (157/162, 96.9%). Of the 181 positive challenges, the symp-
toms of 7 patients (3.9%) were classified as grade I, 56 (30.9%) as
grade II, 92 (51.8%) as grade III and 26 (14.4%) as grade IV (Table 1).
Overall, Ara h 2 was the most frequently recognized peanut allergen
(82.1%), mainly in patients with grade II symptoms or higher (84%‐
100%, see also Table S1 in the online repository). Of the tolerant
subjects and grade I patients 35.5% and 28.6%, respectively, had IgE
against Ara h 2 but with very low levels, that is, geometric mean of
0.09 and 0.16 kUA/L, respectively.
3.2 | Associations of antibody isotype levels with
tolerance and different severity grades
IgE levels to peanut extract were significantly higher in allergic than
tolerant subjects (Figure 1A and Table S2) and increased significantly
with severity (see Figure 1B and Table S2). The same was observed
for IgE against Ara h 1‐ 3, but not against Ara h 8 and Ara h 9. Over-
all, IgE responses against Ara h 2 were clearly the highest except in
tolerant subjects and grade I patients (Table 1 and Figure 1). IgG anti-
body levels against peanut extract, Ara h 1 and Ara h 2, and IgG4
against Ara h 2 were also significantly higher in allergic patients than
tolerant subjects (Figure 2) and increased with severity (Figure 1 and
Table S2). For IgA, no significant associations with tolerance or symp-
tom severity were found (Table S2). Finally, analyses were also per-
formed for ratios of IgG, IgG4, IgA and total IgE over specific IgE
(Figures 2 and 3 and Table S3). In all four cases ratios were signifi-
cantly higher in tolerant than allergic subjects for peanut extract, Ara
h 1‐3 but not for Ara h 8 and Ara h 9. For the same allergens, all four
ratios decreased along with increasing severity of symptoms.
Finally, we analyzed whether thresholds and/or cumulative dose
for objective reactions during challenge were associated with severity.
Although the threshold dose for objective symptoms was not associ-
ated, there was a negative association of severity with the cumulative
dose, independent from sIgE levels to peanut Table 1. Only IgE against
Ara h 2 showed significant but a weak negative correlation after Bon-
ferroni correction with the cumulative dose (ρ−0.252, P = 0.001).
3.3 | Correlations between IgE and non‐IgE
antibody levels
Significant correlations of non‐IgE isotypes with IgE were found for all
allergens in case of IgG and IgG4, and for peanut extract, Ara h 1‐ 3 for
IgA (Figure S1 and S2). The highest correlation coefficients (P < 0.002)
were found for IgE and IgG4 against Ara h 1 (ρ = 0.728), Ara h 8
(ρ = 0.651) and Ara h 2(ρ = 0.625), and for IgE and IgG against whole
peanut (ρ = 0.683), Ara h 1 (ρ = 0.582) and Ara h 2 (ρ = 0.531).
3.4 | Identification of peanut allergic patients and
severity of peanut allergy
To evaluate the diagnostic potential of the different allergen‐specific
antibody isotypes and their ratios, ROC analysis was performed. The
complete results of all ROC analysis are shown in Table S4 and S5
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in the online repository. To distinguish tolerant from allergic subjects,
peanut‐specific (AUC 0.86, 95% CI 0.79‐0.92) and Ara h 2‐specific
IgE (AUC 0.91, 95% CI 0.87‐0.96) performed significantly (P < 0.001)
better than IgG, IgG4 and IgA (AUC between 0.52 and 0.72) (Fig-
ure 4A; Table S4).
Similar results were found when discriminating patients with a
severe peanut allergy (grades III/IV) from those having mild‐to‐
moderate symptoms (Grade I/II) or being tolerant (Figure 4B;
Table S4). The AUCs were highest for IgE against Ara h 2 (0.80,
CI95% 0.73‐0.87) and peanut (0.74, CI95% 0.66‐0.81). All other
AUCs were ≤0.70. Antibody ratios did not provide a better
diagnostic prognostic value compared to IgE alone (Figure 5
and Table S5). AUCs were the same or slightly lower than of
IgE alone.
F IGURE 1 Peanut‐specific antibody levels. Antibody levels are summarized for (A) tolerant vs allergic peanut‐sensitized patients and (B)
stratified for the severity of allergic reactions. The x‐axis represents the serum antibody levels. The symbols and the lines indicate the
geometric mean and the 95% confidence interval (CI) around that mean
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Thresholds for IgE and for the ratios of IgG and IgG4 over IgE to
achieve either optimal sensitivity (~95%) or optimal specificity
(~95%) are summarized in Table S6 and S7 in the online repository.
At a threshold of 0.7 kUA/L for peanut extract and 0.2 kUA/L for Ara
h 2, 95% of the allergic patients were correctly identified (sensitiv-
ity). However, the specificities at these thresholds were low
(24%‐52%). When calculating the highest attainable specificity, we
found the best result for Ara h 2 using ≥1.3 kUA/L as the threshold.
This resulted in a specificity of 92%, sensitivity of 76%, and PPV
and NPV of 98% and 41%, respectively. For the classification of
severe patients, the specificity remained also low when the sensitiv-
ity was ~95%.
4 | DISCUSSION
It has been reported earlier15,26 and now confirmed in the present
study that the ratio of peanut‐specific, and in particular of Ara h 2‐
specific IgG4 over IgE antibody levels is higher in subjects that toler-
ate peanuts than in those that are allergic to peanuts. In several
F IGURE 2 Differences in peanut‐specific IgG/IgE and IgG4/IgE ratios. Serum IgG4 antibody ratios relative to IgE in (A) tolerant vs allergic
peanut‐sensitized patients and (B) stratified for the severity of allergic reactions. The symbols and the lines indicate the geometric mean and
the 95% confidence interval (CI) around that mean
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studies, Ara h 2‐specific IgE has been demonstrated to be a better
diagnostic marker to predict a positive challenge than IgE against
peanut extract.2-9,12
We were interested to know whether ratios of specific IgG4 over
IgE could further improve diagnostic performance. By comparing a
large group of patients with challenge‐proven peanut allergy to toler-
ant peanut‐sensitized subjects, we have now demonstrated that this
is not the case. In the present study, the established dominant role
of Ara h 2 for peanut allergy31 was confirmed in group of 162 pea-
nut‐sensitized allergic and tolerant children and adolescents: by add-
ing Ara h 2‐specific IgG4 into the equation and use ratios over Ara h
2‐specific IgE, the diagnostic prognostic value compared to specific
IgE alone did not improve.
In line with some earlier publications6,9,12,15-17 but opposite to
some others,2,7,18,19 our study found clear support for an association
between sensitization to Ara h 2 and symptom severity during chal-
lenge. Conflicting results in very similarly designed studies such as
the study by Blumchen et al18 and the present study may perhaps
be explained by differences in stop‐criteria during challenge. Here,
we extended the present and published observations in support of
an association between Ara h2‐specific IgE and symptom severity
to demonstrate that it is a good diagnostic discriminator between
mild and severe symptoms during challenge (AUC 0.80, 95% CI
0.73‐0.87).
IgE against peanut allergens is overall higher in patients reacting
to peanuts than those tolerating peanuts, especially in patients with
more severe symptoms, but a large overlap between groups makes it
difficult to accurately discriminate them from each other. The aim of
the present study was to investigate whether specific IgG, IgG4 and/
or IgA levels are related to challenge outcomes, and whether their
measurement may help to improve on the predictive potential of
serum IgE testing. Although still a matter of some debate, IgG4 anti-
bodies are generally thought to be (part of) the working mechanism
of immunotherapy.20 Also, natural exposure to environmental or diet-
ary allergens induces IgG4 antibodies.
32 Recently, the LEAP interven-
tion study25 showed that in young children in the early introduction
intervention group exposed to peanut protein, decreased develop-
ment of peanut allergy was associated with increased IgG4 levels and
IgG4/IgE ratios. The classical hypothesis is that specific IgG4 antibod-
ies play a protective role in allergic disease by blocking IgE binding to
allergens. This would inhibit IgE‐facilitated antigen presentation and
activation of effector cells and could thus explain why some sensi-
tized subjects do not have allergic symptoms to peanut.20 We
observed that in patients with peanut allergy, similar to IgE, specific
IgG and IgG4 levels against peanut Ara h 2 were higher in allergic
than tolerant subjects and increased with symptom severity.
Although apparently contradicting with a protective role, higher levels
of IgG4 against Ara h 2 in allergic patients have been previously
described by Glaumann et al.33 Both IgE, IgG and IgG4 are part of a
Th2‐skewed immune response, and their production is therefore clo-
sely intertwined.32 When however expressed as ratio over IgE, a clear
inverse association was observed with challenge‐proven allergy and
severity of symptoms. This supports a protective role of IgG4 as was
also proposed earlier in reports by Du Toit et al25 and Santos et al.26
How to explain the apparent discrepancy between a positive
association of IgG4 and allergy and symptom severity, and its pro-
posed protective role? Overall, absolute quantities of IgG4 are signifi-
cantly higher than of IgE, both in tolerant subjects and allergic
patients. However, our data show that in patients with IgE levels
>100 ng/mL (> ~40kU/L) the IgG4 levels are comparable. The range
of IgE levels showed an approximately 50.000‐fold difference
between highest and lowest, this was around 5000‐fold for IgG4. This
F IGURE 3 Variation in IgE and IgG4
levels to Ara h 2 and in the IgG4/IgE ratio.
IgE and IgG4 levels to Ara h 2 are
displayed on the left y‐axis for each
patient. All results were converted to ng/
mL. On the right y‐axis, the IgG4/IgE ratios
are given. Patients were ordered on the
x‐axis from those with low levels to high
levels of specific IgE against Ara h 2. The
red dots represent allergic subjects and
black crosses tolerant. The IgG4 levels to
Ara h 2 for that same patient (same
location on the x‐axis) are indicated as pink
dots (allergic) and blue crosses (tolerant).
The IgG4/IgE ratios are indicated as green
squares (tolerant) and purple diamonds
(allergic)
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explains why the ratio of IgG4/IgE decreased with severity while at
the same time IgE and IgG4 levels both increased with the severity of
allergic reactions. The differences in ratios is greatly affected by the
increase of specific IgE, which is much steeper compared to IgG4.
Can differences in IgG4 antibodies improve the predictive accu-
racy compared to IgE against peanut and in particular Ara h 2? The
accuracy of the IgG4/IgE ratio in predicting the outcome of peanut
challenges, with an AUC of 0.86 (95% CI 0.77‐0.94), was comparable
to IgE alone (0.90, 95% CI 0.87‐0.96). Also for the severity of symp-
toms, its predictive accuracy was comparable to that of IgE alone
(AUC 0.76, 95% CI 0.69‐0.84 vs 0.80, 95% CI 0.73‐0.87). Overall, it
is clear that, although IgG4/IgE is significantly associated with protec-
tion in a peanut challenge, in the equation specific IgE on its own is
the decisive risk factor for allergy and severity. Using a cut‐off of
Ara h 2 > 0.6 kUA/L to identify severe patients, we found a sensitiv-
ity of 95% and a NPV of 86.1%, thus ruling out severe peanut
F IGURE 4 Receiver operating characteristic (ROC) curves for specific antibody levels against peanut extract based test and Ara h 2. A,
Predicting the outcome of a positive peanut challenge. B, Predicting outcome of a severe peanut allergy. The P‐values indicate the difference
in performance of IgG, IgG4 and IgA as compared to IgE
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allergy with high certainty. On the other hand, a cut‐off of 47 kUA/L
corresponded to a specificity of 94% and PPV of 90%. High speci-
ficity indicates a low false positive rate (rule in severe reactions) but
the consequence is that ~50% have a negative test and need addi-
tional evaluation.
An important aspect of this study is that these results reflect the
situation in a highly specialized hospital with selected patients with
high likelihood of having true peanut allergy. This consequently affects
the PPV and NPV, since they are highly related to the prevalence of
the outcome measure. All patients that are included have positive IgE
against peanut extract and this will tend to overestimate the discrimi-
natory accuracy of peanut extract but also of the other markers.
5 | CONCLUSION
In conclusion, specific IgG and IgG4 antibody levels are higher in
peanut allergic than in sensitized but tolerant subjects and levels
F IGURE 5 Receiver operating characteristic (ROC) curves for antibody ratios against peanut extract and Ara h 2. A, Predicting the outcome
of a positive peanut challenge. B, Predicting outcome of a severe peanut allergy. The P‐values indicate the difference in performance of the
antibody ratios compared to sIgE alone
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increase with the severity of challenge‐associated symptoms.
Although their ratios over specific IgE are inversely associated with a
positive challenge and with symptom severity, these ratios do not
translate into a better predictive accuracy than with specific IgE
alone. Specific IgE against Ara h 2 is the best biomarker in peanut
allergy diagnosis, both to distinguish allergic from tolerant sensitized
subjects and to estimate the risk of severe reactions.
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